Pharma & EV Stocks Hold Ground in Market Selloff

Pharma Stocks Emerge as a Relative Safe Haven in India's Market Selloff Picture a trading desk on a red Wednesday morning. Nifty is down for the second consecutive session, the broader market is offering little shelter, and fund managers are quietly rotating. The calls aren't going to rate-sensitive banks or consumption plays — they're going to Sun Pharma and Dr. Reddy's. It's a familiar script from past downturns, and it's playing out again. The Sensex extended losses in back-to-back sessions this week, pressured by global macro uncertainty and sustained foreign institutional selling. But pharma stocks — specifically NSE: SUNPHARMA, NSE: DRREDDY, NSE: CIPLA, and NSE: DIVISLAB — held their ground while much of the market didn't. This isn't luck. It's structural. Pharma demand doesn't contract when markets fall. People don't stop buying diabetes medication because the Nifty dropped 400 points. There's a second engine running here too. The rupee's slide against the dollar is directly padding the export revenues of India's large generic manufacturers. For a company like [Dr. Reddy's Laboratories](/stock/DRREDDY), which derives a significant portion of revenue from US generics, every percentage point of rupee depreciation flows into the top line without any corresponding operational effort. That's a real earnings tailwind, not a talking point. What the Numbers Say About Defensive Sector Rotation [Sun Pharmaceutical Industries](/stock/SUNPHARMA) has consistently maintained a FairStock Score above 72, reflecting its balance sheet strength, export mix, and R&D pipeline depth. Cipla and Divi's Laboratories carry similar profile scores — companies with predictable cash flows and limited cyclical exposure. When institutional investors need to park capital defensively without going entirely to cash, large-cap pharma is often the answer. That dynamic is visible in the relative price action this week. The EV angle is less obvious but worth watching. NSE: TATAMOTORS has dra...